

Références des annexes et données supplémentaires

- S1. Albisser AM, Leibel BS, Ewart TG, Davidovac Z, Botz CK, Zingg W. An artificial endocrine pancreas. *Diabetes* 1974; 23:389-396.
- S2. Mirouze J, Selam JL, Pham TC, Cavadore D. Evaluation of exogenous insulin homeostasis by the artificial pancreas in insulin-dependent diabetes. *Diabetologia* 1977; 13:273-278.
- S3. Shichiri M, Kawamori R, Yamasaki Y, Inoue M, Shigeta Y, Abe H; Computer algorithm for the artificial pancreatic beta cell. *Artif Organs* 1978; 2 (Suppl): 247-250.
- S4. Clemens AH, Chang PH, Myers RW. The development of Bio-stator, a glucose-controlled insulin infusion system (GCIIS). *Horm Metab Res* 1977; Supplement: 23-33.
- S5. Mastrototaro J. The MiniMed Continuous Glucose Monitoring System. *Diabetes Technol Ther* 2000; 2 (Supplement 1): S13-S18.
- S6. Cobelli C, Renard E, Kovatchev B. Artificial pancreas: past, present, future. *Diabetes* 60: 2672-82, 2011.
- S7. Kovatchev BP, Breton MD, Dalla Man C, Cobelli C. In Silico Preclinical Trials: A Proof of Concept in Closed-Loop Control of Type 1 Diabetes. *J Diabetes Sci Technol* 2009; 3: 44-55.
- S7. Kovatchev BP, Breton MD, Dalla Man C, Cobelli C. In Silico Preclinical Trials: A Proof of Concept in Closed-Loop Control of Type 1 Diabetes. *J Diabetes Sci Technol*.2009; 3: 44-55.
- S8. Renard E. Implantable closed loop glucose-sensing and insulin delivery: the future for insulin pump therapy. *Curr Opin Pharmacol* 2002; 2:708-716.
- S9. Renard E, Costalat G, Chevassus H, Bringer J. Artificial beta cell: clinical experience toward an implantable closed-loop insulin delivery system. *Diabetes Metab* 2006; 32: 497-502.
- S10. Renard E, Place J, Cantwell M, Chevassus H, Palerm CC. Closed-loop insulin delivery using a subcutaneous glucose sensor and intraperitoneal insulin delivery: feasibility study testing a new model for the artificial pancreas. *Diabetes Care* 2010; 33: 121-127.
- S11. Hovorka R, Chassin LJ, Wilinska ME, Canonico V, Akwi JA, Federici MO, Massi-Benedetti M, Hutzli I, Zaugg C, Kaufmann H, Both M, Vering T, Schaller HC, Schaupp L, Bodenlenz M, Pieber TR. Closing the loop: the ADICOL experience. *Diabetes Technol Ther* 2004; 6: 307-318.
- S12. Steil GM, Rebrin K, Darwin C, Hariri F, Saad MF. Feasibility of automating insulin delivery for the treatment of type 1 diabetes. *Diabetes* 2006; 55: 3344-3350.
- S13. Weinzimer SA, Steil GM, Swan KL, Dziura J, Kurtz N, Tamborlane WV. Fully automated closed-loop insulin delivery versus semi-automated hybrid control in pediatric patients with type 1 diabetes using an artificial pancreas. *Diabetes Care* 2008; 31: 934-939.
- S14. Doyle FJ 3rd, Huyett LM, Lee JB, Zisser HC, Dassau E. Closed-loop artificial pancreas systems: engineering the algorithms. *Diabetes Care* 2014; 37: 1191-1197.
- S15. Hovorka R, Allen JM, Elleri D, Chassin LJ, Harris J, Xing D, Kollman C, Hovorka T, Larsen AM, Nodale M, De Palma A, Wilinska ME, Acerini CL, Dunger DB. Manual closed-loop insulin delivery in children and adolescents with type 1 diabetes: a phase 2 randomised crossover trial. *Lancet* 2010; 375: 743-751.
- S16. Kovatchev B, Cobelli C, Renard E, Anderson S, Breton M, Patek S, Clarke W, Bruttomesso D, Maran A, Costa S, Avogaro A, Dalla Man C, Facchinetti A, Magni L, De Nicolao G, Place J, Farret A. Multinational study of subcutaneous model-predictive closed-loop control in type 1 diabetes mellitus: summary of the results. *J Diabetes Sci Technol* 2010; 4: 1374-1381.

- S17. Patek SD, Magni L, Dassau E, et al; Modular closed-loop control of diabetes. *IEEE Trans Biomedical Eng* 2012; 29: 2986-3000.
- S18. Breton M, Farret A, Bruttomesso D, Anderson S, Magni L, Patek S, Dalla Man C, Place J, Demartini S, Del Favero S, Toffanin C, Hughes-Karvetski C, Dassau E, Zisser H, Doyle FJ 3rd, De Nicolao G, Avogaro A, Cobelli C, Renard E, Kovatchev B; International Artificial Pancreas Study Group Fully integrated artificial pancreas in type 1 diabetes: modular closed-loop glucose control maintains near normoglycemia. *Diabetes* 2012; 61:2230-2237.
- S19. Luijf YM, Devries JH, Zwinderman K, Leelarathna L, Nodale M, Caldwell K, Kumareswaran K, Elleri D, Allen JM, Wilinska ME, Evans ML, Hovorka R, Doll W, Ellmerer M, Mader JK, Renard E, Place J, Farret A, Cobelli C, Del Favero S, Dalla Man C, Avogaro A, Bruttomesso D, Filippi A, Scotton R, Magni L, Lanzola G, Di Palma F, Soru P, Toffanin C, De Nicolao G, Arnolds S, Benesch C, Heinemann L; AP@home Consortium. Day and night closed-loop control in adults with type 1 diabetes mellitus: a comparison of two closed-loop algorithms driving continuous subcutaneous insulin infusion versus patient self-management. *Diabetes Care* 2013; 36: 3882-3887.
- S20. Phillip M, Battelino T, Atlas E, Kordonouri O, Bratina N, Miller S, Biester T, Stefanija MA, Muller I, Nimri R, Danne T. Nocturnal glucose control with an artificial pancreas at a diabetes camp. *N Engl J Med* 2013; 368: 824-833.
- S21. Russell SJ, El-Khatib FH, Nathan DM, Magyar KL, Jiang J, Damiano ER. Blood glucose control in type 1 diabetes with a bi-hormonal bionic endocrine pancreas. *Diabetes Care* 2012; 35: 2148-2155.
- S22. Haidar A, Legault L, Matteau-Pelletier L, Messier V, Dallaire M, Ladouceur M, Rabasa-Lhoret R. Outpatient Overnight Glucose Control With Dual-Hormone Artificial Pancreas, Single-Hormone Artificial Pancreas, or Conventional Insulin Pump Therapy in Children and Adolescents With Type 1 Diabetes: An Open-Label, Randomised Controlled Trial; *Lancet Diabetes Endocrinol* 2015; 3: 595-604.
- S23. Castle JR, El Youssef J, Wilson LM, Reddy R, Resalat N, Branigan D, Ramsey K, Leitschuh J, Rajhbeharrysingh U, Senf B, Sugerman SM, Gabo V, Jacobs PG. Randomized Outpatient Trial of Single- And Dual-Hormone Closed-Loop Systems That Adapt to Exercise Using Wearable Sensors. *Diabetes Care* 2018; 41:1471-1477.
- S24. Ly TT, Breton MD, Keith-Hynes P, De Salvo D, Clinton P, Benassi K, Mize B, Chernavsky D, Place J, Wilson DM, Kovatchev BP, Buckingham BA. Overnight glucose control with automated, unified safety system in children and adolescents with type 1 diabetes at diabetes camp. *Diabetes Care* 2014; 37: 2310-2316.
- S25. Ly TT, Roy A, Grosman D, Shin J, Campbell A, Monirabbasi S, Liang B, von Eyben R, Shanmugham S, Clinton P, Buckingham BA. Day and night closed-loop control using the integrated Medtronic hybrid closed-loop system in type 1 diabetes at diabetes camp. *Diabetes Care* 2015; 38: 1205-1211.
- S26. Russell SJ, El-Khatib FH, Sinha M, Magyar KL, McKeon K, Goergen LG, Balliro C, Hillard MA, Nathan DM, Damiano ER. Outpatient glycemic control with a bionic pancreas in type 1 diabetes. *N Engl J Med* 2014; 371: 313-325.
- S27. Cobelli C, Renard E, Kovatchev BP, Keith-Hynes P, Ben Brahim N, Place J, Del Favero S, Breton M, Farret A, Bruttomesso D, Dassau E, Zisser H, Doyle FJ 3rd, Patek SD, Avogaro A. Pilot studies of wearable outpatient artificial pancreas in type 1 diabetes. *Diabetes Care* 2012, 35: e65-e67.
- S28. Kovatchev BP, Renard E, Cobelli C, Zisser HC, Keith-Hynes P, Anderson SM, Brown SA, Chernavsky DR, Breton MD, Farret A, Pelletier MJ, Place J, Bruttomesso D, Del Favero S, Visentin R, Filippi A, Scotton R, Avogaro A, Doyle FJ 3rd. Feasibility of outpatient fully integrated closed-loop control: First studies of wearable artificial pancreas. *Diabetes Care* 2013; 36: 1851-1858.
- S29. Kovatchev BP, Renard E, Cobelli C, Zisser HC, Keith-Hynes P, Anderson SM, Brown SA, Chernavsky DR, Breton MD, Mize LB, Farret A, Place J, Bruttomesso D, Del Favero S, Boscari F, Galasso S, Avogaro A, Magni L, Di Palma F, Toffanin C, Messori M, Dassau E, Doyle FJ 3rd. Safety of outpatient closed-loop control: first randomized crossover trials of a wearable artificial pancreas. *Diabetes Care* 2014; 37: 1789-1796.

- S30. Del Favero S, Place J, Kropff J, Messori M, Keith-Hynes P, Visentin R, Monaro M, Galasso S, Boscari F, Toffanin C, Di Palma F, Lanzola G, Scarpellini S, Farret A, Kovatchev B, Avogaro A, Bruttomesso D, Magni L, DeVries JH, Cobelli C, Renard E; AP@home Consortium. Multicenter outpatient dinner/overnight reduction of hypoglycemia and increased time of glucose in target with a wearable artificial pancreas using modular model predictive control in adults with type 1 diabetes. *Diabetes Obes Metab* 2015; 17: 468-476.
- S31. Brown SA, Kovatchev BP, Breton MD, Anderson SM, Keith-Hynes P, Patek SD, Jiang B, Ben Brahim N, Vereshchetin P, Bruttomesso D, Avogaro A, Del Favero S, Boscari F, Galasso S, Visentin R, Monaro M, Cobelli C. . Multinight « bedside » closed-loop control for patients with type 1 diabetes. *Diabetes Technol Ther* 2015; 17:203-209.
- S32. Nimri R, Muller I, Atlas E, Miller S, Fogel A, Bratina N, Kordonouri O, Battelino T, Danne T, Phillip M. MD-Logic overnight control for 6 weeks of home use in patients with type 1 diabetes: randomized crossover trial. *Diabetes Care* 2014; 37:3025-3032.
- S33. Thabit H, Lubina-Solomon A, Stadler M, Leelarathna L, Walkinshaw E, Pernet A, Allen JM, Iqbal A, Choudhary P, Kumareswaran K, Nodale M, Nisbet C, Wilinska ME, Barnard KD, Dunger DB, Heller SR, Amiel SA, Evans ML, Hovorka R. Home use of closed-loop insulin delivery for overnight glucose control in adults with type 1 diabetes: a 4-week, multicentre, randomised crossover study. *Lancet Diabetes Endocrinol* 2014; 2:701-709.
- S34. Kropff J, Del Favero S, Place J, Toffanin C, Visentin R, Monaro M, Messori M, Di Palma F, Lanzola G, Farret A, Boscari F, Galasso S, Magni P, Avogaro A, Keith-Hynes P, Kovatchev BP, Bruttomesso D, Cobelli C, DeVries JH, Renard E, Magni L; AP@home consortium. 2 month evening and night closed-loop glucose control in patients with type 1 diabetes under free-living conditions: a randomised crossover trial. *Lancet Diabetes Endocrinol* 2015; 3: 939-947.
- S35. Renard E, Farret A, Kropff J, Bruttomesso D, Messori M, Place J, Visentin R, Calore R, Toffanin C, Di Palma F, Lanzola G, Magni P, Boscari F, Galasso S, Avogaro A, Keith-Hynes P, Kovatchev B, Del Favero S, Cobelli C, Magni L, DeVries JH; AP@home Consortium. Day-and-Night Closed-Loop Glucose Control in Patients With Type 1 Diabetes Under Free-Living Conditions: Results of a Single-Arm 1-Month Experience Compared With a Previously Reported Feasibility Study of Evening and Night at Home. *Diabetes Care* 2016; 39: 1151-1160.
- S36. Thabit H, Tauschmann M, Allen JM, Hartnell S, Wilinska ME, Acerini CL, Dellweg S, Benesch C, Heinemann L, Mader JK, Holzer M, Kojzar H, Exall J, Yong J, Pichierrri J, Barnard KD, Kollman C, Cheng P, Hindmarsh PC, Campbell FM, Arnolds S, Pieber TR, Evans ML, Dunger DB, Hovorka R. Home use of an artificial beta cell in type 1 diabetes. *N Engl J Med* 2015; 373: 2129-2140.
- S37. Anderson SM, Raghinaru D, Pinsky JE, Boscari F, Renard E, Buckingham BA, Nimri R, Doyle FJ 3rd, Brown SA, Keith-Hynes P, Breton MD, Chernavvsky D, Bevier WC, Bradley PK, Bruttomesso D, Del Favero S, Calore R, Cobelli C, Avogaro A, Farret A, Place J, Ly TT, Shanmugham S, Phillip M, Dassau E, Dasanayake IS, Kollman C, Lum JW, Beck RW, Kovatchev B; Control to Range Study Group. Multinational home use of closed-loop control is safe and effective. *Diabetes Care* 2016; 39: 1143-1150.
- S38. Kovatchev B, Cheng P, Anderson SM, Pinsky JE, Boscari F, Buckingham BA, Doyle FJ 3rd, Hood KK, Brown SA, Breton MD, Chernavvsky D, Bevier WC, Bradley PK, Bruttomesso D, Del Favero S, Calore R, Cobelli C, Avogaro A, Ly TT, Shanmugham S, Dassau E, Kollman C, Lum JW, Beck RW. Feasibility of long-term closed-loop control: a multicenter 6-month trial of 24/7 automated insulin delivery. *Diabetes Technol Ther* 2017; 19:18-24.
- S39. Tauschmann M, Thabit H, Bally L, Allen JM, Hartnell S, Wilinska ME, Ruan Y, Sibayan J, Kollman C, Cheng P, Beck RW, Acerini CL, Evans ML, Dunger DB, Elleri D, Campbell F, Bergenstal RM, Criego A, Shah VN, Leelarathna L, Hovorka R; APCam11 Consortium. Closed-loop Insulin Delivery in Suboptimally Controlled Type 1 Diabetes: A Multicentre, 12-week Randomised Trial. *Lancet* 2018; 392:1321-1329.
- S40. Barnard KD, Wysocki T, Ullly V, Mader JK, Pieber TR, Thabit H, Tauschmann M, Leelarathna L, Hartnell S, Acerini CL, Wilinska ME, Dellweg S, Benesch C, Arnolds S, Holzer M, Kojzar H, Campbell F, Yong J, Pichierrri J, Hindmarsh P, Heinemann L, Evans ML, Hovorka R. Closing the Loop in Adults, Children and Adolescents With Suboptimally Controlled Type 1 Diabetes Under Free Living Conditions: A Psychosocial Substudy. *J Diabetes Sci Technol* 2017; 11:1080-1088.

- S41. Kropff J, DeJong J, Del Favero S, Place J, Messori M, Coestier B, Farret A, Boscari F, Galasso S, Avogaro A, Bruttomesso D, Cobelli C, Renard E, Magni L, DeVries JH; AP@home consortium. Psychological outcomes of evening and night closed-loop insulin delivery under free living conditions in people with Type 1 diabetes: a 2-month randomized crossover trial. *Diabet Med* 2017; 34: 262-271.
- S42. Benhamou PY, Franc S, Reznik Y, Thivolet C, Schaepelynck P, Renard E, Guerci B, Chaillous L, Lukas-Croisier C, Jeandidier N, Hanaire H, Borot S, Doron M, Jallon P, Xhaard I, Melki V, Meyer L, Delemer B, Guillouche M, Schoumaker-Ley L, Farret A, Raccach D, Lablanche S, Joubert M, Penfornis A, Charpentier G on behalf of Diabeloop WP7 trial investigators.. Closed loop insulin delivery in adults with type 1 diabetes in real life conditions: a multicentre, 12-week randomised crossover trial. On behalf of diabeloop trial investigators. *Lancet Digit Health* 2019; 1: e17-25.
- S43. Barnard KD, Venkat MV, Close K, Heinemann L, Weissberg-Benchell J, Hood KK, Kubiak T, Kowalski AJ, Laffel L. PsychDT Working Group: Report Psychosocial Aspects of Artificial Pancreas Systems. *J Diabetes Sci Technol* 2015; 9:925-928.
- S44. Hovorka R, Elleri D, Thabit H, Allen JM, Leelarathna L, El-Khairi R, Kumareswaran K, Caldwell K, Calhoun P, Kollman C, Murphy HR, Acerini CL, Wilinska ME, Nodale M, Dunger DB. Overnight closed-loop insulin delivery in young people with type 1 diabetes: a free-living, randomized clinical trial. *Diabetes Care* 2014; 37:1204-11.
- S45. Tauschmann, M., Allen, J.M., Wilinska, M.E., Thabit, H., Acerini, C.L., Dunger, D.B., and Hovorka, R. Home Use of Day-and-Night Hybrid Closed-Loop Insulin Delivery in Suboptimally Controlled Adolescents With Type 1 Diabetes: A 3-Week, Free-Living, Randomized Crossover Trial. *Diabetes Care* 2016; 39: 2019–2025.
- S46. Isganaitis E, Raghinaru D, Ambler-Osborn L, et al for iDCL Trial Research Group. Closed-loop control (CLC) in teens and young adults improves glycemic control: results from 6-month multicenter Randomized Clinical Trial (RCT). *Pediatr Diabetes* 2019;20(Suppl 28):232.
- S47. Messer LH, Forlenza GP, Sherr JL, Wadwa RP, Buckingham BA, Weinzimer SA, Maahs DM, Slover RH. Optimizing Hybrid Closed-Loop Therapy in Adolescents and Emerging Adults Using the MiniMed 670G System. *Diabetes Care*. 2018;41:789-796.
- S48. Garg SK, Weinzimer SA, Tamborlane WV, Buckingham BA, Bode BW, Bailey TS, Brazg RL, Ilany J, Slover RH, Anderson SM, Bergenstal RM, Grosman B, Roy A, Cordero TL, Shin J, Lee SW, Kaufman FR. Glucose Outcomes with the In-Home Use of a Hybrid Closed-Loop Insulin Delivery System in Adolescents and Adults with Type 1 Diabetes. *Diabetes Technol. Ther* 2017;19, 155–163.
- S49. Weisman A, Bai JW, Cardinez M, Kramer CK, Perkins BA. Effect of artificial pancreas systems on glycaemic control in patients with type 1 diabetes: a systematic review and meta-analysis of outpatient randomised controlled trials. *Lancet Diabetes Endocrinol* 2017; 5:501-512.
- S50. Bekiari E, Kitsios K, Thabit H, Tauschmann M, Athanasiadou E, Karagiannis T, Haidich AB, Hovorka R, Tsapas A. Artificial pancreas treatment for outpatients with type 1 diabetes: systematic review and meta-analysis. *BMJ* 2018; 361:k1310.
